Sutro Biopharma (STRO) Change in Account Payables (2017 - 2025)

Sutro Biopharma has reported Change in Account Payables for 9 years, with the latest figure at $575000.0 in Q4 2025.

• Quarterly Change in Account Payables fell 86.05% year-over-year to $575000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.5 million (down 449.58% YoY) and the FY2025 annual result came in at -$2.5 million, down 449.58% from the prior year.
• Change in Account Payables slipped to $575000.0 in Q4 2025 per STRO's latest filing, from $2.7 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.1 million in Q4 2024 and troughed at -$3.8 million in Q2 2025.
• A 5-year average of $226650.0 and a median of -$292500.0 in 2021 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables plunged 1058.08% in 2024, then surged 2281.3% in 2025.
• Over 5 years, Change in Account Payables stood at -$1.8 million in 2021, then surged by 47.24% to -$937000.0 in 2022, then surged by 532.98% to $4.1 million in 2023, then increased by 1.58% to $4.1 million in 2024, then plunged by 86.05% to $575000.0 in 2025.
• According to Business Quant data, Change in Account Payables over the past three periods registered $575000.0, $2.7 million, and -$3.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.